Abstract
Introduction: Bimekizumab (BKZ) has demonstrated superior clinical responses to adalimumab (ADA), ustekinumab (UST), and secukinumab (SEC) in patients with moderate to severe plaque psoriasis. Number needed to treat (NNT) is a clinically meaningful way to assess comparative effectiveness between treatments, indicating how many patients need to be treated for one additional patient to achieve an outcome vs a comparator.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
